BamSEC and AlphaSense Join Forces
Learn More

Collegium Pharmaceutical Inc.

NASDAQ: COLL    
Share price (12/27/24): $29.11    
Market cap (12/27/24): $649 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 4 pages ​ Letter Agreement ​
12/34/56
EX-10.2
from 10-Q 9 pages Separation and Release Agreement
12/34/56
EX-10.1
from 10-Q 26 pages ​ Certain Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. ​ Authorized Generic Agreement
12/34/56
EX-10.4
from 10-K 4 pages Collegium Pharmaceutical, Inc. Amended and Restated 2014 Stock Incentive Plan
12/34/56
EX-10.7
from 10-Q 13 pages Employment Agreement
12/34/56
EX-10.6
from 10-Q 2 pages January 20, 2022 via E-Mail Re: Amendment to Employment Agreement Dear Scott: Reference Is Hereby Made to the Amended and Restated Employment Agreement Effective as of January 1, 2021 (The “Employment Agreement”) by and Between You and Collegium Pharmaceutical, Inc. (The “Company”). Effective as of the Date of This Letter, the Company and You Agree to Amend the Employment Agreement as Follows: 1.section 5 of the Employment Agreement Is Hereby Amended by Renumbering Section 5.1.5 as Section 5.1.6 and Adding a New Section 5.1.5 Which Reads as Follows
12/34/56
EX-10.5
from 10-Q 2 pages January 20, 2022 via E-Mail Re: Amendment to Employment Agreement Dear Shirley: Reference Is Hereby Made to the Amended and Restated Employment Agreement Effective as of January 1, 2021 (The “Employment Agreement”) by and Between You and Collegium Pharmaceutical, Inc. (The “Company”). Effective as of the Date of This Letter, the Company and You Agree to Amend the Employment Agreement as Follows: 1.section 5 of the Employment Agreement Is Hereby Amended by Renumbering Section 5.1.5 as Section 5.1.6 and Adding a New Section 5.1.5 Which Reads as Follows
12/34/56
EX-10.4
from 10-Q 2 pages January 20, 2022 via E-Mail Re: Amendment to Employment Agreement Dear Colleen: Reference Is Hereby Made to the Employment Agreement Effective as of May 24, 2021 (The “Employment Agreement”) by and Between You and Collegium Pharmaceutical, Inc. (The “Company”). Effective as of the Date of This Letter, the Company and You Agree to Amend the Employment Agreement as Follows: 1.section 5 of the Employment Agreement Is Hereby Amended by Renumbering Section 5.1.5 as Section 5.1.6 and Adding a New Section 5.1.5 Which Reads as Follows
12/34/56
EX-10.3
from 10-Q 2 pages January 20, 2022 via E-Mail Re: Amendment to Employment Agreement Dear Joe: Reference Is Hereby Made to the Amended and Restated Employment Agreement Dated as of December 27, 2020 (The “Employment Agreement”) by and Between You and Collegium Pharmaceutical, Inc. (The “Company”). Effective as of the Date of This Letter, the Company and You Agree to Amend the Employment Agreement as Follows: 1.section 5 of the Employment Agreement Is Hereby Amended by Renumbering Section 5.1.5 as Section 5.1.6 and Adding a New Section 5.1.5 Which Reads as Follows
12/34/56
EX-10.1
from 8-K 135 pages Certain Identified Information Has Been Excluded From This Exhibit in Accordance With Regulation S-K Item 601(a)(6) Because It Would Constitute a Clearly Unwarranted Invasion of Personal Privacy. [***] Indicates That Information Has Been Redacted
12/34/56
EX-10.1
from 8-K 14 pages Form of Tender and Support Agreement
12/34/56
EX-10.1
from SC TO-C 14 pages Form of Tender and Support Agreement
12/34/56
EX-10.1
from 10-Q 13 pages Employment Agreement
12/34/56
EX-10.6
from 8-K 13 pages Amended & Restated Employment Agreement
12/34/56
EX-10.5
from 8-K 13 pages Amended & Restated Employment Agreement
12/34/56
EX-10.4
from 8-K 13 pages Amended & Restated Employment Agreement
12/34/56
EX-10.3
from 8-K 13 pages Amended & Restated Employment Agreement
12/34/56
EX-10.2
from 8-K 13 pages Amended & Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 14 pages Amended & Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 28 pages Certain Portions of the Exhibit That Are Not Material and Would Be Competitively Harmful if Publicly Disclosed Have Been Redacted Pursuant to Item 601(b)(10)(iv) of Regulation S-K. [***] Indicates That Information Has Been Redacted. Settlement Agreement
12/34/56